NIKKEI 225
38,255.49 -18.56 (-0.05%) HANG SENG
18,184.76 +421.73 (+2.37%) CRUDE OIL
79.52 +0.52 (+0.66%) GOLD FUTURES
2,325.30 +14.30 (+0.62%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,765.93 -2,031.43 (-4.25%)
Genprex, Inc. (0A8I.L)
| Previous close | 2.1701 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 2,261 |
| Market cap | N/A |
| Beta (5Y monthly) | -0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3950 |
| Earnings date | 22 May 2024 - 26 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireGenprex to Present and Participate at Upcoming May Investor and Industry Conferences
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in May 2024.
PR NewswireGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 America
ZacksGenprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
